{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:50:42Z","timestamp":1793998242039,"version":"4.8.0"},"reference-count":137,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is characterized by a complex disruption of hemostatic balance, increasing the risk of both thrombotic and hemorrhagic events. Thrombotic complications, most notably portal vein thrombosis (PVT) and venous thromboembolism (VTE), have a significant impact on clinical outcomes and therapeutic strategies. Cirrhosis contributes to the precarious equilibrium between pro- and anticoagulant forces through impaired synthesis of coagulation factors, endothelial dysfunction, and systemic inflammation. In the presence of HCC tumor-driven mechanisms, such as tissue factor expression, extracellular vesicle release, platelet activation, and suppression of fibrinolysis exacerbate this prothrombotic state. In this scenario, advanced diagnostic tools such as thrombin generation assay (TGA) and rotational thromboelastometry (ROTEM) offer a more accurate assessment of coagulation dynamics than conventional tests, enabling better risk stratification especially for therapeutic purposes. Anticoagulant therapy has demonstrated clinical benefit in selected cases of non-malignant PVT and VTE, particularly when liver function is preserved. While prophylactic strategies are still under investigation, data suggest they may be safely implemented in selected surgical patients. In the setting of immunotherapy, especially regimens involving anti-VEGF agents, anticoagulation may be considered with careful management of bleeding risk due to portal hypertension. An individualized approach to anticoagulation, supported by functional coagulation testing, is gaining acceptance as a means to safely reduce thrombotic burden and potentially improve outcomes in patients with HCC.<\/jats:p>","DOI":"10.3390\/cancers17213413","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:35:11Z","timestamp":1761269711000},"page":"3413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thrombotic Risk and Coagulation Imbalance in Cirrhosis and Hepatocellular Carcinoma: Clinical Implications and Management"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-0803","authenticated-orcid":false,"given":"Leonardo","family":"Stella","sequence":"first","affiliation":[{"name":"Liver Unit, CEMAD Centro Malattie del\u2019Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1024-1541","authenticated-orcid":false,"given":"Matteo","family":"De Siati","sequence":"additional","affiliation":[{"name":"Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3934-3775","authenticated-orcid":false,"given":"Rosa","family":"Talerico","sequence":"additional","affiliation":[{"name":"Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pallozzi","sequence":"additional","affiliation":[{"name":"Liver Unit, CEMAD Centro Malattie del\u2019Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-7582","authenticated-orcid":false,"given":"Lucia","family":"Cerrito","sequence":"additional","affiliation":[{"name":"Liver Unit, CEMAD Centro Malattie del\u2019Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-7815","authenticated-orcid":false,"given":"Silvia","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6230-1779","authenticated-orcid":false,"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Liver Unit, CEMAD Centro Malattie del\u2019Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-2819","authenticated-orcid":false,"given":"Erica","family":"De Candia","sequence":"additional","affiliation":[{"name":"Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-2931","authenticated-orcid":false,"given":"Roberto","family":"Pola","sequence":"additional","affiliation":[{"name":"Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-6238","authenticated-orcid":false,"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[{"name":"Liver Unit, CEMAD Centro Malattie del\u2019Apparato Digerente, Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Translational Medicine and Surgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/JTS.1000182","article-title":"Hemostasis, bleeding and thrombosis in liver disease","volume":"3","author":"Flores","year":"2017","journal-title":"J. Transl. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A Meta-Analysis of Case Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding in Patients with Cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","article-title":"Incidence of venous thromboembolism in patients hospitalized with cancer","volume":"119","author":"Stein","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2011.12.034","article-title":"Portal vein thrombosis, cirrhosis, and liver transplantation","volume":"57","author":"Francoz","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1111\/liv.15001","article-title":"Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure","volume":"41","author":"Campello","year":"2021","journal-title":"Liver Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/hep4.1641","article-title":"Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis","volume":"5","author":"Zanetto","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/hep.1840160515","article-title":"The incidence of portal vein thrombosis at liver transplantation","volume":"16","author":"Nonami","year":"1992","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/00007890-199404270-00006","article-title":"Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation","volume":"57","author":"Davidson","year":"1994","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0b013e318206818b","article-title":"Portal vein thrombosis and liver transplantation: Evolution during 10 years of experience at the University of Bologna","volume":"253","author":"Ravaioli","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.thromres.2007.10.009","article-title":"Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma","volume":"122","author":"Connolly","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1477-2574.2012.00479.x","article-title":"Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: Analysis of 5651 National Surgical Quality Improvement Program patients","volume":"14","author":"Tzeng","year":"2012","journal-title":"HPB"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trre.2014.01.003","article-title":"Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up","volume":"28","author":"Ponziani","year":"2014","journal-title":"Transplant. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2016.12.019","article-title":"Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma","volume":"49","author":"Zanetto","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1499-3872(16)60092-9","article-title":"Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients","volume":"15","author":"Cagin","year":"2016","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1076029617699088","article-title":"Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients with Hepatocellular Carcinoma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/CEG.S172663","article-title":"D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis","volume":"11","author":"Malaguarnera","year":"2018","journal-title":"CEG"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0038-1676981","article-title":"Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients","volume":"119","author":"Violi","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12029-019-00242-9","article-title":"Correlates, Trends, and Short-Term Outcomes of Venous Thromboembolism in Hospitalized Patients with Hepatocellular Carcinoma","volume":"50","author":"Mohammed","year":"2019","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e04677","DOI":"10.1016\/j.heliyon.2020.e04677","article-title":"Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma","volume":"6","author":"Serag","year":"2020","journal-title":"Heliyon"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis","volume":"9","author":"Senzolo","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_26","first-page":"1006","article-title":"Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease","volume":"122","author":"Ow","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.dld.2020.12.103","article-title":"Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma","volume":"53","author":"Grasso","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s11739-022-02928-8","article-title":"Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients","volume":"17","author":"Faccia","year":"2022","journal-title":"Intern. Emerg. Med."},{"key":"ref_29","first-page":"1581","article-title":"Portal vein thrombosis in patients with hepatocellular carcinoma and early cirrhosis\u2014Prevalence and risk factors","volume":"17","author":"Siddiqui","year":"2023","journal-title":"eCancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-010-9166-6","article-title":"Deep vein thrombosis in patients with advanced liver cirrhosis: A rare condition?","volume":"4","author":"Lesmana","year":"2010","journal-title":"Hepatol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.thromres.2016.05.021","article-title":"Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis","volume":"143","author":"Campello","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.dld.2025.01.054","article-title":"Efficacy and safety of atezolizumab\/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: A 2024 update","volume":"57","author":"Stefanini","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.hpb.2020.09.008","article-title":"Development and validation of a risk calculator for post-discharge venous thromboembolism following hepatectomy for malignancy","volume":"23","author":"Schlick","year":"2021","journal-title":"HPB"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2147\/JHC.S311970","article-title":"Construction and Validation of a Nomogram for Predicting the Risk of Deep Vein Thrombosis in Hepatocellular Carcinoma Patients After Laparoscopic Hepatectomy: A Retrospective Study","volume":"8","author":"Chen","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, L., Liu, D., He, W., and Zhang, W. (2025). Incidence of thrombosis in patients with hepatocellular carcinoma: Systematic review and meta-analysis. J. Thromb. Thrombolysis.","DOI":"10.1007\/s11239-025-03143-w"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The Coagulopathy of Chronic Liver Disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_37","first-page":"e23785","article-title":"Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management","volume":"14","author":"Islam","year":"2022","journal-title":"Cureus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep4.1781","article-title":"More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients with Cirrhosis with Versus without HCC","volume":"5","author":"Zanetto","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jtha.2025.02.034","article-title":"Patients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype","volume":"23","author":"Willems","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/liv.15183","article-title":"Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: Laboratory evidence and clinical implications","volume":"42","author":"Zanetto","year":"2022","journal-title":"Liver Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/10760296221104797","article-title":"The Efficacy and Safety of Anticoagulants in the Treatment of Cirrhotic Portal Vein Thrombosis: A Systematic Review and Meta-Analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/jth.15312","article-title":"Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?","volume":"19","author":"Groeneveld","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.13500","article-title":"Decreased Portal Vein Velocity is Predictive of the Development of Portal Vein Thrombosis: A Matched Case-Control Study","volume":"38","author":"Stine","year":"2017","journal-title":"Liver Int."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Airola, C., Severino, A., Porcari, S., Fusco, W., Mullish, B.H., Gasbarrini, A., Cammarota, G., Ponziani, F.R., and Ianiro, G. (2023). Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics, 12.","DOI":"10.3390\/antibiotics12050868"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Galasso, L., Cerrito, L., Termite, F., Mignini, I., Esposto, G., Borriello, R., Galasso, L., Cerrito, L., Termite, F., and Mignini, I. (2024). The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16193247"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"156385","DOI":"10.1016\/j.cyto.2023.156385","article-title":"Aberrant cytokine and VCAM-1 expression in patients with viral and non-viral related liver cirrhosis","volume":"171","author":"Afifi","year":"2023","journal-title":"Cytokine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Jiang, S., Ai, Y., Ni, L., Wu, L., Huang, X., and Chen, S. (2022). Platelet-derived TGF-\u03b21 is related to portal vein thrombosis in cirrhosis by promoting hypercoagulability and endothelial dysfunction. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.938397"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Terbah, R., Testro, A., Gow, P., Majumdar, A., and Sinclair, M. (2023). Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis\u2014Pathogenesis, Implications and Therapeutic Opportunities. Nutrients, 16.","DOI":"10.3390\/nu16010035"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/tri.13873","article-title":"Portal vein thrombosis and renal dysfunction: A national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis","volume":"34","author":"Molinari","year":"2021","journal-title":"Transpl. Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.dld.2023.09.012","article-title":"Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients","volume":"56","author":"Dalbeni","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.01.001","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"He, Q., Yang, J., and Jin, Y. (2022). Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief. Bioinform., 23.","DOI":"10.1093\/bib\/bbac291"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ahmadi, S.E., Shabannezhad, A., Kahrizi, A., Akbar, A., Safdari, S.M., Hoseinnezhad, T., Zahedi, M., Sadeghi, S., Golizadeh Mojarrad, M., and Safa, M. (2023). Tissue factor (coagulation factor III): A potential double-edge molecule to be targeted and re-targeted toward cancer. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00504-6"},{"key":"ref_54","first-page":"5339","article-title":"Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma","volume":"9","author":"Poon","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.3748\/wjg.v10.i17.2472","article-title":"Thrombocytosis: A paraneoplastic syndrome in patients with hepatocellular carcinoma","volume":"10","author":"Hwang","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1007\/s13277-015-3487-y","article-title":"Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: A meta-analysis","volume":"36","author":"Zhong","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"861","DOI":"10.31557\/APJCP.2020.21.3.861","article-title":"Epithelial Cell Adhesion Molecule mRNA Can be a Potential Marker to Predict Metastasis in Hepatocellular Carcinoma Patients","volume":"21","author":"Abdelgawad","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.bjc.6605689","article-title":"Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma","volume":"102","author":"Wang","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.21037\/jgo-21-343","article-title":"Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma","volume":"12","author":"Niu","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Azam, A., Klisic, A., Mercantepe, F., Faseeh, H., Mercantepe, T., and Rafaqat, S. (2025). Role of Coagulation Factors in Hepatocellular Carcinoma: A Literature Review. Life, 15.","DOI":"10.3390\/life15010034"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12964-020-00634-6","article-title":"Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis","volume":"18","author":"Marquard","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3892\/ol.2022.13404","article-title":"Hypoxia-inducible factor-1\u03b1: A critical target for inhibiting the metastasis of hepatocellular carcinoma","volume":"24","author":"Chen","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chun, K. (2022). Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071380"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.gendis.2017.10.003","article-title":"Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma","volume":"4","author":"Amr","year":"2017","journal-title":"Genes Dis."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zanetto, A., Senzolo, M., Campello, E., Bulato, C., Gavasso, S., Shalaby, S., Gambato, M., Vitale, A., Cillo, U., and Farinati, F. (2021). Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. Cancers, 13.","DOI":"10.3390\/cancers13051150"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/jth.13752","article-title":"The impact of initial cancer stage on the incidence of venous thromboembolism: The Scandinavian Thrombosis and Cancer (STAC) Cohort","volume":"15","author":"Gade","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/liv.14560","article-title":"Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000489833","article-title":"Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma","volume":"8","author":"Scheiner","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.thromres.2021.12.027","article-title":"The role of P-selectin in cancer-associated thrombosis and beyond","volume":"213","author":"Yeini","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cca.2010.11.026","article-title":"Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer","volume":"412","author":"Ferroni","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Giuli, L., Pallozzi, M., Venturini, G., Gasbarrini, A., Ponziani, F.R., and Santopaolo, F. (2023). Molecular Mechanisms Underlying Vascular Liver Diseases: Focus on Thrombosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612754"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2499029","DOI":"10.1080\/07853890.2025.2499029","article-title":"The emerging roles of platelet-derived extracellular vesicles in disease","volume":"57","author":"Lou","year":"2024","journal-title":"Ann. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/cvr\/cvae138","article-title":"Intraplatelet miRNA-126 regulates thrombosis and its reduction contributes to platelet inhibition","volume":"120","author":"Zhang","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Xiao, Q., Wang, D., Sheng, Y., Huang, J., and Ha, X. (2023). MicroRNA-126 Regulates Thrombosis Through Endothelial Progenitor Cells. DNA Cell Biol., 42.","DOI":"10.1089\/dna.2022.0643"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000355502","article-title":"Elevated Plasma Fibrinogen Levels Are Associated with a Poor Prognosis in Patients with Hepatocellular Carcinoma","volume":"85","author":"Kinoshita","year":"2013","journal-title":"Oncology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.annonc.2020.04.146","article-title":"P-64 P-selectin and factor VIII as risk factors of thromboembolic disease in patients with hepatocellular carcinoma","volume":"31","author":"Chudej","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/liv.14493","article-title":"AB0, von Willebrand factor\/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?","volume":"40","author":"Bitto","year":"2020","journal-title":"Liver Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"goac065","DOI":"10.1093\/gastro\/goac065","article-title":"Low ADAMTS-13\/VWF ratio and altered gut-liver axis predict complications of advanced chronic liver disease: A pilot study","volume":"10","author":"Ponziani","year":"2022","journal-title":"Gastroenterol. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.dld.2022.06.004","article-title":"ADAMTS-13\/von Willebrand factor ratio: A prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study","volume":"54","author":"Sacco","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Suda, T., Takatori, H., Hayashi, T., Kaji, K., Nio, K., Terashima, T., Shimakami, T., Arai, K., Yamashita, T., and Mizukoshi, E. (2023). Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097732"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1076029611427900","article-title":"Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis","volume":"18","author":"Alkim","year":"2012","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1160\/TH10-06-0413","article-title":"Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells","volume":"105","author":"Lin","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000505191","article-title":"How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT","volume":"9","author":"Bae","year":"2020","journal-title":"Liver Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?","volume":"8","author":"Abdelhamed","year":"2024","journal-title":"Liver Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s43066-022-00201-3","article-title":"Diagnosis of portal vein thrombosis in cirrhotic patients with and without hepatocellular carcinoma","volume":"12","author":"Serag","year":"2022","journal-title":"Egypt. Liver J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.neo.2020.09.007","article-title":"Epigenome-wide DNA methylation profiling of portal vein tumor thrombosis (PVTT) tissues in hepatocellular carcinoma patients","volume":"22","author":"Fan","year":"2020","journal-title":"Neoplasia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/tcr-22-2069","article-title":"FAM83D promotes the proliferation and migration of hepatocellular carcinoma cells by inhibiting the FBXW7\/MCL1 pathway","volume":"11","author":"Nie","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Xu, F., Zhang, L., Xu, Y., Song, D., He, W., Ji, X., and Shao, J. (2020). Hypermethylation of SCAND3 and Myo1g Gene Are Potential Diagnostic Biomarkers for Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12082332"},{"key":"ref_89","first-page":"5450","article-title":"Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma","volume":"15","author":"Wang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1535370220963197","article-title":"Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5","volume":"246","author":"Li","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13046-020-01576-0","article-title":"Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1","volume":"39","author":"Song","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Nenu, I., Toadere, T.M., Topor, I., \u021aichindeleanu, A., Bondor, D.A., Trella \u0218erban, E., Sparchez, Z., and Filip, G.A. (2023). Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102623"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Xiao, Z., Yeung, C.L.S., Yam, J.W.P., and Mao, X. (2022). An update on the role of complement in hepatocellular carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1007382"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e24433","DOI":"10.1002\/jcla.24433","article-title":"Neutrophil extracellular traps are associated with enhanced procoagulant activity in liver cirrhosis patients with portal vein thrombosis","volume":"36","author":"Xing","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/gutjnl-2022-327924","article-title":"MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression","volume":"72","author":"Fu","year":"2023","journal-title":"Gut"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1659","DOI":"10.1002\/wrna.1659","article-title":"The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response","volume":"12","author":"Favero","year":"2021","journal-title":"WIREs RNA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.3390\/ijms15057711","article-title":"Importance of Kupffer Cells in the Development of Acute Liver Injuries in Mice","volume":"15","author":"Tsutsui","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Casari, M., Siegl, D., Deppermann, C., and Schuppan, D. (2023). Macrophages and platelets in liver fibrosis and hepatocellular carcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1277808"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Huang, X., Zhang, Y., Yi, S., Lei, L., Ma, T., Huang, R., Yang, L., Li, Z.M., and Zhang, D. (2023). Potential contribution of the gut microbiota to the development of portal vein thrombosis in liver cirrhosis. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1217338"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Qi, P., Yang, X., Wang, C., Sang, W., Zhang, W., and Bai, Y. (2025). Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1597145"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jtha.2024.12.036","article-title":"Gut microbiome dysbiosis is not associated with portal vein thrombosis in patients with end-stage liver disease: A cross-sectional study","volume":"23","author":"Aleksandrova","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.thromres.2013.06.009","article-title":"Whole blood rotation thromboelastometry (ROTEM\u00ae) profiles in subjects with non-neoplastic portal vein thrombosis","volume":"132","author":"Rossetto","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"101065","DOI":"10.1016\/j.jhepr.2024.101065","article-title":"Atezolizumab\/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events","volume":"6","author":"Jochheim","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.21266","article-title":"Thrombin generation in patients with cirrhosis: The role of platelets","volume":"44","author":"Tripodi","year":"2006","journal-title":"Hepatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e2961","DOI":"10.1002\/brb3.2961","article-title":"The investigation on the hypercoagulability of hepatocellular carcinoma-related cerebral infarction with thromboelastography","volume":"13","author":"Cen","year":"2023","journal-title":"Brain Behav."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/jth.14751","article-title":"Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay","volume":"18","author":"Wan","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Drotarova, M., Zolkova, J., Belakova, K.M., Brunclikova, M., Skornova, I., Stasko, J., and Simurda, T. (2023). Basic Principles of Rotational Thromboelastometry (ROTEM\u00ae) and the Role of ROTEM-Guided Fibrinogen Replacement Therapy in the Management of Coagulopathies. Diagnostics, 13.","DOI":"10.3390\/diagnostics13203219"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.jceh.2024.102409","article-title":"Rotational Thromboelastometry Reduces the Need for Preemptive Transfusion in Cirrhosis: A Randomized Controlled Trial (NCT:05698134)","volume":"15","author":"Kumar","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"10760296221123310","DOI":"10.1177\/10760296221123310","article-title":"Assessment of Rotational Thromboelastometry and Thrombin Generation Assay to Identify Risk of High Blood Loss and Re-Operation After Cardiac Surgery","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/JHC.S390777","article-title":"Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients","volume":"10","author":"Benevento","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/HEP.0000000000000538","article-title":"Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC","volume":"79","author":"Senzolo","year":"2024","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3138\/canlivj.2018-0026","article-title":"HCC complicated by PVT: Outcome and the role of anticoagulation therapy","volume":"2","author":"Mahmoudi","year":"2019","journal-title":"Can. Liver J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40644-024-00657-z","article-title":"Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion","volume":"24","author":"Balcar","year":"2024","journal-title":"Cancer Imaging"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e16212","DOI":"10.1200\/JCO.2023.41.16_suppl.e16212","article-title":"Anticoagulation for portal vein thrombosis in patients with hepatocellular carcinoma: A retrospective observational study","volume":"41","author":"Antonios","year":"2023","journal-title":"JCO"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1111\/liv.70114","article-title":"Safety of Anticoagulant Treatment in Patients with Splanchnic Vein Thrombosis and History of Portal Hypertension-Related Bleeding","volume":"45","author":"Talerico","year":"2025","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/liv.14992","article-title":"Safety of direct oral anticoagulants in patients with advanced liver disease","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jhep.2025.06.035","article-title":"Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study","volume":"83","author":"Puente","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1245\/s10434-018-6671-7","article-title":"Venous Thromboembolic Events Following Major Pelvic and Abdominal Surgeries for Cancer: A Prospective Cohort Study","volume":"25","author":"Serrano","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3748\/wjg.v16.i17.2146","article-title":"Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: Is it necessary?","volume":"16","author":"Vivarelli","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Zhang, X., and Ai, Z. (2025). Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04208-z"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/jth.13814","article-title":"Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective","volume":"15","author":"Kim","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: Guidance from the SSC of the ISTH","volume":"22","author":"Carlin","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2019.02.003","article-title":"Efficacy and safety of direct oral anticoagulant therapy for the treatment of venous thromboembolism in patients with chronic liver disease","volume":"176","author":"Davis","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1055\/s-0039-1697682","article-title":"Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry","volume":"45","author":"Bikdeli","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/bloodadvances.2022007961","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: An individual patient data meta-analysis","volume":"6","author":"Candeloro","year":"2022","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism","volume":"392","author":"Carrier","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2036.2010.04454.x","article-title":"The epidemiology and clinical features of portal vein thrombosis: A multicentre study","volume":"32","author":"Rajani","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100591","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international propensity score matching analysis","volume":"7","author":"Rimini","year":"2022","journal-title":"ESMO Open"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kim, B.K., Cheon, J., Kim, H., Kang, B., Ha, Y., Kim, D.Y., Hwang, S.G., Chon, Y.E., and Chon, H. (2022). Atezolizumab\/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers, 14.","DOI":"10.3390\/cancers14071747"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"17588359211031141","DOI":"10.1177\/17588359211031141","article-title":"Immunotherapy in hepatocellular carcinoma: Evaluation and management of adverse events associated with atezolizumab plus bevacizumab","volume":"13","author":"Hsu","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"101120","DOI":"10.1016\/j.jhepr.2024.101120","article-title":"Anticoagulation is not associated with an increased risk of variceal bleeding under systemic therapy for advanced HCC","volume":"6","author":"Allaire","year":"2024","journal-title":"JHEP Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/liv.15918","article-title":"Safety\/efficacy of atezolizumab + bevacizumab during anti-platelet\/anticoagulation therapy in unresectable hepatocellular carcinoma","volume":"44","author":"Moriguchi","year":"2024","journal-title":"Liver Int."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e7430","DOI":"10.1002\/cam4.7430","article-title":"Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants","volume":"13","author":"Nakabori","year":"2024","journal-title":"Cancer Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/liv.15458","article-title":"A history of variceal bleeding is associated with further bleeding under atezolizumab\u2013bevacizumab in patients with HCC","volume":"42","author":"Larrey","year":"2022","journal-title":"Liver Int."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T01:50:46Z","timestamp":1761270646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/21\/3413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":137,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17213413"],"URL":"https:\/\/doi.org\/10.3390\/cancers17213413","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}